Abstract
The immunosuppressive drugs Cyclosporine A (CSA) and prednisolone are widely used to prevent graftversus- host-disease (GVHD) after allogenetic stem cell transplantation (allo-SCT). However, it remains to be elucidated whether these drugs have an effect on the balance of effector cells and CD4+CD25+ regulatory T cells (Tregs) which determines the development of stable allograft tolerance. In the current study, we found that proliferation, activation and function of T cells especially for virus-specific CD8+ T cells and Tregs were inhibited by CSA and prednisolone in a dosedependent manner. These effects were associated with lower secretion of cytokines and arresting T cells in the G0/G1 phase of cell cycle. Moreover, CSA and prednisolone could reduce the expression of FOXP3 and suppressive function of Tregs. Our data indicated that CSA and prednisolone impaired the development and function of CD8+ T cells as well as Tregs in a similar way suggesting that CSA and prednisolone might increase the susceptibility to develop viral diseases and block the potential induction of immune tolerance in clinical settings.
Keywords: T cells, cyclosporine A, prednisolone
Current Signal Transduction Therapy
Title: The Inhibitory Effect of Cyclosporine A and Prednisolone on Both Cytotoxic CD8+ T Cells and CD4+CD25+ Regulatory T Cells
Volume: 4 Issue: 3
Author(s): Fei Fei, Yingzhe Yu, Anita Schmitt, Markus Thomas Rojewski, Baoan Chen, Marlies Gotz, Philippe Guillaume, Donald Bunjes and Michael Schmitt
Affiliation:
Keywords: T cells, cyclosporine A, prednisolone
Abstract: The immunosuppressive drugs Cyclosporine A (CSA) and prednisolone are widely used to prevent graftversus- host-disease (GVHD) after allogenetic stem cell transplantation (allo-SCT). However, it remains to be elucidated whether these drugs have an effect on the balance of effector cells and CD4+CD25+ regulatory T cells (Tregs) which determines the development of stable allograft tolerance. In the current study, we found that proliferation, activation and function of T cells especially for virus-specific CD8+ T cells and Tregs were inhibited by CSA and prednisolone in a dosedependent manner. These effects were associated with lower secretion of cytokines and arresting T cells in the G0/G1 phase of cell cycle. Moreover, CSA and prednisolone could reduce the expression of FOXP3 and suppressive function of Tregs. Our data indicated that CSA and prednisolone impaired the development and function of CD8+ T cells as well as Tregs in a similar way suggesting that CSA and prednisolone might increase the susceptibility to develop viral diseases and block the potential induction of immune tolerance in clinical settings.
Export Options
About this article
Cite this article as:
Fei Fei, Yu Yingzhe, Schmitt Anita, Rojewski Thomas Markus, Chen Baoan, Gotz Marlies, Guillaume Philippe, Bunjes Donald and Schmitt Michael, The Inhibitory Effect of Cyclosporine A and Prednisolone on Both Cytotoxic CD8+ T Cells and CD4+CD25+ Regulatory T Cells, Current Signal Transduction Therapy 2009; 4 (3) . https://dx.doi.org/10.2174/157436209789057502
DOI https://dx.doi.org/10.2174/157436209789057502 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evaluating Intestinal Permeability by Measuring Plasma Endotoxin and Diamine Oxidase in Children with Acute Lymphoblastic Leukemia Treated with High-dose Methotrexate
Anti-Cancer Agents in Medicinal Chemistry Eosinophils in Cancer: Favourable or Unfavourable?
Current Medicinal Chemistry OX40 and OX40L Interaction in Cancer
Current Medicinal Chemistry Royal Jelly Acid, 10-Hydroxy-trans-2-Decenoic Acid, as a Modulator of the Innate Immune Responses
Endocrine, Metabolic & Immune Disorders - Drug Targets Aurora A and B Kinases - Targets of Novel Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is Promising
Current Drug Metabolism The Impact of CRISPR/Cas9-Based Genomic Engineering on Biomedical Research and Medicine
Current Molecular Medicine Epidemiology and Prevention of Viral Infections in Patients with Hematologic Malignancies
Infectious Disorders - Drug Targets The Potential of Flavonoids and Tannins from Medicinal Plants as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Driving Neural Stem Cells Towards a Desired Phenotype
Current Stem Cell Research & Therapy The PA207 Peptide Inhibitor of LIM-only Protein 2 (Lmo2) Targets Zinc Finger Domains in a Non-specific Manner
Protein & Peptide Letters Cytotoxic Nucleoside Analogues: Different Strategies to Improve their Clinical Efficacy
Current Medicinal Chemistry Ciprofloxacin Stress Proteome of the Extended-Spectrum β-lactamase Producing Escherichia coli from Slaughtered Pigs
Current Proteomics Eriocalyxin B-Induced Apoptosis in Pancreatic Adenocarcinoma Cells Through Thiol-Containing Antioxidant Systems and Downstream Signalling Pathways
Current Molecular Medicine Deregulation of Apoptosis - Is it Still an Important Issue in Pathogenesis of Chronic Lymphocytic Leukemia?
Current Cancer Drug Targets Economics of Pharmacogenomics: Rethinking Beyond QALYs?
Current Pharmacogenomics and Personalized Medicine From Na+/K+-ATPase and Cardiac Glycosides to Cytotoxicity and Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets n-3 Polyunsaturated Fatty Acids and the Prevention of Colorectal Cancer: Molecular Mechanisms Involved
Current Medicinal Chemistry Cytotoxic Effects on B Lymphocytes Mediated by Reactive Oxygen Species
Current Pharmaceutical Design